Precision targeted cancer-associated fibroblast nano-regulator enhanced chemo-immunotherapy for triple-negative

Peng Xian1, Linghui Zou1, Jiaxin Zhang1

  • 1School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.

Biomaterials
|September 12, 2025
PubMed

Insights

Targeting cancer-associated fibroblasts (CAFs) with novel nanoparticles (TET@ACNP) effectively inhibits triple-negative breast cancer (TNBC) growth. This strategy enhances chemotherapy and boosts anti-tumor immunity by modulating the tumor microenvironment.

Area of Science:

  • Oncology
  • Nanomedicine
  • Cancer Biology

Background:

  • Cancer-associated fibroblasts (CAFs) are key components of the triple-negative breast cancer (TNBC) tumor microenvironment.
  • CAFs contribute to tumor growth, chemoresistance, and immunosuppression by forming a dense stromal barrier.
  • Targeting CAFs presents a promising therapeutic strategy for TNBC, but lacks specific markers for precise targeting.

Purpose of the Study:

  • To design a nanoparticle-based drug delivery system for precise targeting and modulation of CAFs in TNBC.
  • To evaluate the efficacy of the designed nanoparticle in inhibiting CAF activation, overcoming chemoresistance, and enhancing anti-tumor immunity.

Main Methods:

  • Development of a nanoparticle (TET@ACNP) co-modified with anisamide and CAF cell membrane (CAFm) to load tetrandrine.
  • Utilizing CAFm homing and anisamide-sigma receptor interaction for precise CAF targeting.
  • Assessing the impact of TET@ACNP on CAF activation, collagen secretion, drug penetration, immune cell infiltration, Wnt/β-catenin pathway, and IGF2 expression.

Main Results:

  • TET@ACNP precisely targeted and modulated CAFs, inhibiting their activation and reducing collagen secretion.
  • The nanoparticle broke down the stromal barrier, facilitating docetaxel (DTX) penetration and cytotoxic T lymphocyte infiltration.
  • TET@ACNP alleviated chemoresistance by inhibiting the Wnt/β-catenin pathway and suppressed IGF2, thereby releasing the immunosuppressive microenvironment.

Conclusions:

  • Precise targeting and regulation of CAFs using TET@ACNP offer a multifaceted approach to inhibit TNBC.
  • This strategy enhances chemotherapy efficacy and boosts anti-tumor immunity.
  • The developed platform holds potential for improving therapeutic outcomes in various stroma-rich tumors.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K